UPDATE 1-Allergan says U.S. FDA delays Semprana decision, OKs Ozurdex

June 30, 2014 1:47 PM

17 0

June 30 (Reuters) - Allergan Inc said on Monday the U.S. Food and Drug Administration had raised issues about its application for a new acute migraine aerosol but had separately approved a treatment for diabetic macular edema.

Allergan, the Botox maker that is fighting off a hostile bid from Valeant Pharmaceuticals International Inc, said the FDA had approved its Ozurdex sustained-release biodegradable steroid implant as a new treatment option for some patients with diabetic macular edema.

Read more

To category page